Exogenous and Endogenous Glucocorticoids in Rheumatic Diseases

Charité University Medicine Berlin and Berlin-Brandenburg Center of Regenerative Therapies, Berlin, Germany.
Arthritis & Rheumatology (Impact Factor: 7.87). 01/2011; 63(1):1-9. DOI: 10.1002/art.30070
Source: PubMed


Available from: Rainer H Straub, Oct 22, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Osteocalcin is a bone-specific protein that is regularly used in the clinical setting as a serum marker of bone turnover. Recent evidence indicates that osteocalcin plays a previously unsuspected role in the control of energy metabolism. Thus, osteocalcin-deficient mice have a profoundly deranged metabolic phenotype that includes insulin resistance, glucose intolerance and abnormal fat deposition. Additionally, osteocalcin administration in mice improves insulin sensitivity and decreases fat pad mass and serum triglyceride levels. The role of osteocalcin in human macronutrient metabolism is less clear but recent studies report positive correlations between serum osteocalcin levels and established indices of metabolic health. Herein, we review key physiological functions of osteocalcin, focussing on the roles of osteocalcin in the modulation of macronutrient metabolism, male reproductive function and foetal brain development. We consider the implications of these findings for the coordination of metabolism with development and fertility. We also consider evidence that a Class C G-protein-coupled receptor from a subgroup known to mediate nutrient-sensing acts as the osteocalcin receptor.
    Calcified Tissue International 11/2014; 96(1). DOI:10.1007/s00223-014-9931-y · 2.75 Impact Factor
  • 01/2013; 8(1):1-7. DOI:10.1016/S1634-6939(12)49792-7
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glucocorticoids play a pivotal role in the management of many inflammatory rheumatic diseases. The therapeutic effects range from pain relief in arthritides, to disease-modifying effects in early rheumatoid arthritis, and to strong immunosuppressive actions in vasculitides and systemic lupus erythematosus. There are multiple indications that adverse effects are more frequent with the longer use of glucocorticoids and use of higher dosages, but high-quality data on the occurrence of adverse effects are scarce especially for dosages above 10 mg prednisone daily. The underlying rheumatic disease, disease activity, risk factors and individual responsiveness of the patient should guide treatment decisions. Monitoring for adverse effects should also be tailored to the patient. Continuously balancing the benefits and risks of glucocorticoid therapy is recommended. There is an ongoing quest for new drugs with glucocorticoid actions without the potential to cause harmful effects, such as selective glucocorticoid receptor agonists, but the application of a new compound in clinical practice will probably not occur within the next few years. In the meantime, basic research on glucocorticoid effects and detailed reports on therapeutic efficacy and occurrence of adverse effects will be valuable in weighing benefits and risks in clinical practice.
    Arthritis Research & Therapy 11/2014; 16 Suppl 2(Suppl 2):S2. DOI:10.1186/ar4686 · 4.12 Impact Factor